Home

-

  • 60,000+ Australians hospitalised each year for heart failure

  • 60+ years of collaboration in CVD

  • 100+ clinician researchers

  • Pipeline of cardiovascular clinician-research talent

The Monash Alfred Baker Centre for Cardiovascular Research will create collaborative opportunities for academic-clinician partnered research and new pathways for clinical researchers at the Alfred Precinct.

Flagship programs

Artificial Heart Frontiers Program (AHFP)

The world-first long-term artificial heart revolutionises the next-generation of implantable heart devices. The Artificial Heart Frontiers Program (AHFP) brings together clinicians, engineers and scientists to develop long-term solutions for patients with heart failure. Access to the technology will save millions of lives globally, and improve quality of life and productivity.

Visit the AHFP

-

Our capabilities and expertise

A partnership between

-

Cardiovascular news highlights

Monash-Alfred-Baker join forces to improve heart health

A new cardiovascular research centre is bringing together Monash University, the Baker Heart and Diabetes Institute and Alfred Health to boost opportunities for academic-clinician partnered research and offer new pathways for emerging research talent in the Alfred Research Alliance Precinct.

Find out more

Mending broken hearts: The next generation of implantable heart devices

In Australia, heart failure affects 500,000 people with more 50,000 new diagnoses annually. Globally, more than 64 million patients are affected, and with an aging population the prevalence is rising.

Heart failure is typically a progressive condition and patients commonly experience worsening quality of life, frequent hospitalisations and, ultimately, reduced life expectancy.

Find out more

Breakthrough valve clip procedure offers new hope

An innovative procedure being performed in The Alfred’s Heart Centre is giving new hope to patients suffering from a life-threatening condition.

‘Heart in a box’ now a proven gamechanger

Two Alfred heart experts have today declared a new method of donor heart preservation a gamechanger for heart transplantation in Australia and New Zealand.

Clinical trials create hope for the future

Of all clinical trials happening in Australia, one in five occur on site at The Alfred. The Alfred does two thirds of all first-in-human clinical trials conducted in Australia.

Melbourne dad saved by Australian-first trial

When 43-year-old Melbourne dad Mark Wohlers suffered a cardiac arrest last year, it was the swift emergency response and an Australian-first clinical trial that gave him a second chance at life.

Visualising heart disease to communicate risk improves patient adherence

Visualising early heart disease using cardiac imaging helps with patient understanding of risk and adherence to medication and lifestyle change, according to a new study.

MRFF Cardiovascular Health Grant

Professor David Kaye and Associate Professor Bing Wang have been granted close to $1M in MRFF funding to develop inhibitors for an enzyme known to be a critical factor in the development of the predominant form of heart failure, HFpEF (Heart failure

Trial of AI-assisted voice analysis to identify changes in heart failure

Australian researchers will trial AI-assisted voice analysis to evaluate breathlessness and disease severity in people with heart failure with the aim of providing a cheap and accessible home monitoring tool.

Innovation through AI and cardiology: Monash-Alfred-Baker meet-up sparks collaborative conversations

The Monash Alfred Baker Centre discussed AI's role in heart health, merging experts from science, IT, engineering, clinical care, and industry, delving into solutions for cardiac issues.

Contact us

Interested to find out more about clinician-led cardiovascular research at the Alfred precinct?
Connect with our team today - D.Kaye@alfred.org.au